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ABSTRACT

Background: United States Preventive Services Task Force (USPSTF) and Centers for
Medicare & Medicaid Services (CMS) recommendations for annual screening for lung cancer
with low dose CT (LDCT) scans rely on age and smoking history to identify those at high risk for
lung cancer. The Tammemagi et al. six year lung cancer risk prediction model, PLCOm2012,
developed and validated in large lung cancer screening clinical trials, demonstrated good
predictive performance in screening selection. However, the model has not been validated in
clinical practice. Validating the model in clinical practice would increase confidence in its ability
to provide information for shared decision making discussions in the near term and would
potentially allow for selection of other high risk groups, not currently recommended to be
screened, in the future.
Methods: Retrospective evaluation of the predictive performance of the Tammemagi et al. six
year lung cancer risk prediction model in the Lahey Hospital & Medical Center, Lahey physician
referred patients enrolled in the lung cancer screening program between January 1, 2012 and
November 30, 2015 (n=2302). Predictor variable data were gathered from the program clinical
data base and program participant clinic medical records. All patients met the National
Comprehensive Cancer Network (NCCN) Lung Cancer Screening Guidelines Group 1 or Group
2 high-risk criteria.
Results: The model six year mean risk for lung cancer was higher for participants with lung
cancer, 4.56%, as compared to those without lung cancer, 3.55% (p=0.0265). Area under the
curve (AUC) of the receiver operator characteristics (ROC) was 0.63 (95% CI 0.57 – 0.69). The
mean absolute difference between observed and predicted risk was 0.013 or less for the first 9
deciles. At the 1.51% predicted risk recommended screening threshold; sensitivity = 85.7%,
specificity = 29.7%, and PPV = 3.7%. In sub-group analysis, for NCCN Group 2 (younger,
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lighter smoking history, no limit on time quit and one additional risk factor) the mean predicted
risk for participants with lung cancer was 2.39% as compared to 1.83% for those without lung
cancer but the difference was not statistically significant; p=0.2507. However, the incidence of
lung cancer was the same for NCCN Group 2 as for the complete sample. NCCN Group 2
model AUC was 0.634 (95% CI 0.522 – 0.746), the sensitivity and specificity of the model at the
recommended screening threshold were 64.7% and 56.0%, respectively and PPV was 4.2%.
Conclusions: Lung cancer risk prediction model, PLCOm2012noEd, predictive performance in
a clinical lung cancer screening program was adequate to help patients and their physicians
assess individual risk of lung cancer relative to the recommended model risk screening
threshold (1.51%) and to supplement USPSTF and CMS screening program entry criteria for
shared decision making discussions. Model risk predictive capability for the NCCN Group 2
subgroup did not match actual screening program lung cancer results.
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Chapter 1: Introduction
The burden of lung cancer on US society is high. The cost of medical care for lung cancer is
projected to be $14.8 billion per year by 2020; 8.5% of the total cost of medical care for all
cancers.1 Lost productivity contributes another $38.9 billion per year2; 27% of the total for all
cancers. Lung cancer claims almost 160,000 lives a year; more than colon, breast, pancreatic,
and prostate cancer combined.3 Almost twice as many women die of lung cancer as die of
breast cancer.3 There are 221,000 newly diagnosed cases every year; about 65% of them in
never or former smokers.3

The $250 million National Lung Screening Trial (NLST) was the first to show that annual
screening for lung cancer with low dose CT (LDCT) scans reduced lung cancer mortality.4 The
NLST was a large randomized controlled clinical trial comparing annual screening with LDCT
scan to chest x-ray (CXR). 53,456 current and former heavy smokers were enrolled between
2002 and 2004 and were randomized to either 3 annual screenings with LDCT or CXR. After
6.5 years of follow-up, the LDCT group had a 20% lower mortality than the CXR group.4

The NLST was stopped in November 2010 after an interim review showed the 20% reduction in
mortality for the LDCT arm. The results of the trial were published on-line by the New England
Journal of Medicine in June of 2011.4 The primary endpoint was lung cancer mortality.
Secondary endpoints included all-cause mortality, lung cancer incidence, and screening and
treatment related morbidity.5 Shortly afterwards, in the fall of 2011, the National Comprehensive
Cancer Network (NCCN) published guidelines for lung cancer screening.6 The guidelines
recommended screening 2 groups; NCCN Group 1 was essentially the NLST group; ages 55 to
74, 30 or more pack year smoking history, current or former smokers quit within the last 15
years. People in NCCN Group 2 were > 50 years, 20 or more pack year history of smoking,
current or former smokers with no limit on time quit and with at least one additional risk factor; a
1

personal history of a smoking related malignancy, a history of lung cancer in a first degree
relative, having COPD or pulmonary fibrosis, or exposure to one or more of several known
carcinogens including radon, asbestos, silica, cadmium, and diesel fumes. A 30 pack year
history would be smoking a pack a day for 30 years or 2 packs a day for 15 years or essentially
any combination of packs per day and years of smoking that add up to 30.

Lung cancer screening programs were started at several medical institutions across the US
after the publication of the NLST results and the NCCN guidelines. Screening criteria were not
uniform across the sites. Some screened only the NLST population (same as NCCN Group 1)
some screened both NCCN Group 1 and 2. The Lahey Hospital & Medical Center (Lahey)
started their Rescue Lung, Rescue Life community benefit lung cancer screening program in
Jan 2012 and offered screening to both NCCN Group 1 and 2.7,8 Lahey has the largest clinical
lung cancer screening program in the US having screened over 3600 patients to date and
performed nearly 8000 LDCT scans.

Lung cancer screening with LDCT scan is now recommended by the United States Preventive
Services Task Force (USPSTF) and Centers for Medicare & Medicaid Services (CMS) and
covered by private insurance and Medicare/Medicaid for a group of high risk current and former
smokers.9,10 This group includes people from age 55 to 77 (55-80 for USPSTF), current and
former smokers quit within the last 15 years, with a 30 or greater pack year smoking history.
There are estimated to be approximately eight million people in the United States that are
eligible for lung cancer screening.9 Screening this recommended high risk group is predicted to
save 722,000 to 1,625,000 quality adjusted life years (years of life left adjusted for health related
quality of life) over a 15 year period and to save 12,500 lives per year.9 The criteria for
screening are not inclusive of most patients meeting the NCCN Group 2 recommended to
screen guidelines.
2

The CMS guidelines for screening include a required separate shared decision making (SDM)
visit with a qualified health care practitioner, essentially a physician or a nurse practitioner,
including use of a decision aid (DA) prior to entering a lung cancer screening program.10

The decision to undergo lung cancer screening involves tradeoffs between early detection and
the potential for false positives, the risk of a surgical intervention for benign disease, the risk for
treatment of indolent disease, and exposure to radiation (similar to a mammogram) every
year.11 Use of a risk prediction model as part of the shared decision making discussion helps to
individualize the probability of lung cancer and provides patients and physicians with better
information for shared decision making.

Chapter 2: The Study
The study is a retrospective IRB approved evaluation of the predictive performance of a six year
lung cancer risk prediction model using the Lahey Rescue Lung, Rescue Life lung cancer
screening program clinical data base and program participant clinic medical records for Lahey
physician referred patients enrolled in the lung cancer screening program between January 1,
2012 and November 30, 2015. The model is an independently developed risk prediction model,
developed using the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial
data,2,13 and validated with both PLCO and NLST data, for the six year probability of developing
lung cancer.
Goal
The goal of the study is to evaluate the predictive capability of a reparameterized Tammemagi
et al.13 PLCOm2012 lung cancer screening risk prediction model in a clinical lung cancer
screening program.
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Hypothesis: The PLCOm2012 validated 6 year lung cancer risk prediction model,
reparametrized without the education predictor variable, will show significant correlation of
predicted risk to lung cancers found in a large US clinical LDCT scan lung cancer screening
program.
Primary objective: Evaluate the predictive performance of the reparametrized Tammemagi
PLCOm2012 six year lung cancer risk prediction model in a clinical lung cancer screening
program.
Secondary objective: Evaluate the predictive performance of the reparametrized Tammemagi
PLCOm2012 six year lung cancer risk prediction model, for the subgroup of patients meeting
the NCCN Group 2 criteria for lung cancer screening, in a clinical lung cancer screening
program.
Chapter 3: Background
The CMS requirement for a shared decision making visit using one or more decision aides prior
to entering a lung cancer screening program is the first time reimbursement has been tied to the
use of decision aids and shared decision making.
Despite many recommendations to use decision aids,14-16 shared decision making is not widely
used in clinical practice.17 Surveys of primary care physicians and pulmonologists, those most
likely to recommend LDCT screening for patients, show a lack of awareness of LDCT screening
and a lack of understanding of screening guidelines and requirements.18,19 Although DAs and
SDM are sometimes used in prostate, colon and breast cancer screening, 20-23 they are not a
requirement for CMS reimbursement as they are for lung cancer screening.
A recent Cochrane update of decision aids concluded that there was high quality evidence to
show use of decision aides improved patient knowledge about options and reduced decisional
conflict as compared to standard practice.20,24 There was medium quality evidence that use of
decision aides increased patient involvement in decision making and improved risk perceptions
4

when probabilities were included in the decision aid.* All of the included studies were
randomized clinical trials.
Since shared decision making and the use of a decision aid is required for CMS reimbursement
for lung cancer screening, it is important to assess the performance of lung cancer risk models
in the clinical setting. Having an individualized predicted risk of lung cancer during the shared
decision making discussion can help the patient and the physician in the decision to enter or not
enter a lung cancer screening program.
A study of existing cancer risk prediction models found that many are being made available in
the primary care setting.25 The study identified several challenges for implementing these
models including, choosing the “right” risk model and setting the threshold for intervention.
Choosing a risk threshold for cancer screening is a trade between sensitivity and specificity, or
in other words, a trade between finding more cancers with an increased possibility of a false
positive (low risk selection threshold) and finding fewer cancers but having fewer false positives
(higher selection risk threshold).
Although there are several lung cancer risk models that have been developed over the last 10 to
15 years,26,27 the only one validated with the NLST data was the Tammemagi et al. six year
lung cancer risk prediction model, PLCOm2012.13 The model predicts an individual’s probability
of developing lung cancer in the next six years based on their individual risk factors. This model
was initially developed and validated in the PLCO Cancer Screening Trial,12 and subsequently
modified for NLST criteria and validated with NLST data.13 The results showed good predictive
value for the validation data set and the model was more sensitive than the NLST criteria for
lung cancer screening selection.13 Both the USPSTF and CMS lung cancer screening guidelines

*

High quality of evidence indicated research is very unlikely to change the confidence in the estimate of the effect
and medium quality that further research is likely to have an impact on the confidence of the estimate of the effect
and may change it.
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were based on the NLST.9,10 The PLCOm2012 was the only model validated with the NLST data
and also had the best predictive performance for risk of lung cancer,26,27 thus it was the model
chosen for this study. Additionally, some of the other models had predictor variables that were
not available for the study clinical lung screening program sample.27
The PLCOm2012 model is available for free download in Excel from Brock University.28 The
model is also used as part of the web-based, University of Michigan-developed, lung cancer
screening decision aid.29 However, the predictive capability of the PLCOm2012 model has not
been evaluated in a clinical lung cancer screening program.
The USPSTF and CMS criteria for selecting screening participants are based on age, smoking
history and time since quit smoking for former smokers.9,10 Tammemagi et al. have presented
analyses showing selection of screening participants may be improved by using the
PLCOm2012 six year probability of developing lung cancer model.30 Comparing results in the
PLCO smoker intervention group sample using the PLCOm2012 risk threshold of 1.51% vs.
USPSTF criteria resulted in improved sensitivity, specificity, and PPV.30 Lung cancer screening
risk models are not currently approved to be used for selecting participants for lung cancer
screening. Participants in a clinical lung cancer screening program must meet USPSTF/CMS
criteria to be eligible for insurance or Medicare reimbursement.
Evidence that USPSTF/CMS screening selection may not include many at high risk of lung
cancer includes a recent journal article that assessed the use of a reparameterized
PLCOm2012 model (family history of lung cancer predictor variable removed) to predict risk of
lung cancer using National Health and Nutrition Examination Survey (NHANES) data and
compared the results to CMS screening selection criteria.31 The results from the study showed
that more African American men than men of other races/ethnicities had high model predicted
six year risk of lung cancer without meeting the CMS screening selection criteria. More
Hispanics had low model predicted six year risk of lung cancer but met the CMS screening
6

selection criteria. This would result in fewer high risk African Americans meeting screening
criteria and getting screened; potentially increasing the current disparity in lung cancer mortality
between African American men (75.7 deaths per 100,000 per year) and other demographic
groups (average all groups 45.8 deaths per 100,000 per year).31 It may also result in more
Hispanic men with lower risk of lung cancer entering screening programs with less potential
benefits and greater potential harms.
Another recent study did a secondary analysis of the PLCO lung cancer data and found that
current smokers with a 20 to 29 pack year history of smoking have a similar risk of lung cancer
as former smokers, quit 15 years or less, with a 30 or more pack year history of smoking.32 The
group of former smokers, quit 15 years or less with a 30 pack year history are eligible for
screening while current smokers with a 20 to 29 pack year history are not.
Two other recent studies retrospectively evaluated whether people with a lung cancer diagnosis
would have been eligible for screening based on USPSTF screening criteria. One study
evaluated the predicted risk in lung cancer patients that had undergone resection and compared
the risk for those meeting and those not meeting USPSTF screening criteria to recommended
screening risk probability thresholds. The Tammemagi PLCOm2012 model was used to
calculate predicted risk. Almost 50% of those not meeting USPSTF criteria had model predicted
risk levels above the model screening risk threshold.33 The other study found that two thirds of
people with lung cancer in 2 cohorts of almost 6000 patients in Olmstead County, Minnesota did
not meet USPSTF screening selection criteria.34
Identifying and expanding the lung cancer screening selection criteria to others at equivalent or
higher risk without another large randomized study will likely require a model based approach.
Validating a lung cancer risk model in clinical practice would be a first step in using the model
for lung cancer screening selection potentially addressing high risk individuals not eligible for
screening under the current guidelines. Development and validation of lung cancer screening
7

risk prediction models are also critical for refining and improving the selection of screening
participants to maximize the benefits and minimize the harms of screening. Confidence in use of
risk models for screening participant selection will improve with demonstrated model
performance in clinical lung cancer screening programs.
To my knowledge, this study is the first to evaluate the predictive capability of any lung cancer
risk prediction model in a clinical lung cancer screening program.
Chapter 4: Pedigree of the Screening Program Study Model
The Tammemagi et al. initial lung cancer risk prediction model, PLCOm2011, was developed
and validated in the PLCO Cancer Screening Trial participants.12 The PLCO was an NIH
sponsored general population multi-center randomized controlled trial that enrolled 154,901
people ages 55 to 74, with no known cancers, between 1993 and 2001.35 For lung cancer
screening, the intervention was four screenings with chest x-ray, a baseline and 3 annual
screens, with follow-up to year 13 or December 2009.36 Never smokers were not screened after
April 1995.36 The control arm was usual medical care with follow-up for up to 13 years after
enrollment or to December 2009.36
Two models predicting the risk of developing lung cancer in the next 9 years were developed; a
general population model and an ever smoker model.12 The general population model was
developed using prospective data from 70,962 participants; the smoker model used a sub-group
of 38,254 participants. Follow-up was for a median of 9.2 years (inter-quartile range 7.5 -10.7).
The validation data set had 44,223 PLCO intervention arm participants.
Both models were binary logistic regression models. Logistic regression models have binary
outcomes (dependent variables) and include predictor variables that can be both categorical
and continuous. The outcome for both of these models was a binary indicator of a lung cancer
diagnosis. Predictor variables for the second model, the ever smoker model, PLCOm2011, were
8

age, level of education, BMI, family history of lung cancer, COPD, having had a chest x-ray in
the previous 3 years, current or former smoker status, pack year smoking history, duration of
smoking and, for former smokers, time quit.
The Tammemagi et al. six year lung cancer risk prediction model, PLCOm2012, was a
modification of the PLCOm2011 ever smoker model, described in the previous paragraph, to
make it compatible with the shorter follow up time in the NLST study data and included lung
cancers identified through the first 6 years of follow-up.13
Tammemagi et al. developed the PLCOm2012 model using the PLCO control group of current
and former smokers with follow-up truncated at 6 years.13 Their stated approach was to
consider predictor variables for inclusion that were literature- recognized lung cancer risk factors
and all of the PLCOm2011 predictor variables.13 They validated the PLCOm2012 model in the
PLCO intervention group of current and former smokers, the NLST group and the PLCO
intervention group participants that met NLST entry criteria.13 The primary difference for the
latter group being in the NLST requirement for a 30 pack year or greater smoking history and
less than 15 years quit while PLCO enrolled participants with any smoking history, including
never smokers. Thus the PLCO subgroup of former and current smokers (used for model
development) included long term quit light smokers while the NLST did not.
As compared to PLCOm2011, the PLCOm2012 model predictor variables included race/ethnic
group and personal history of cancer and didn’t include history of a chest x-ray in the last 3
years. Pack years smoking history was split into 2 variables, smoking intensity and smoking
duration. Smoking intensity (average number of cigarettes smoked per day) had a non-linear
association with the outcome variable. The treatment of the non-linear effect used multivariable
fractional polynomials.26 The treatment of non-linear variables varied between the 2 models.
The PLCOm2011 used restricted cubic splines for treatment of non-linear variables.26

9

For this study, I retrospectively evaluated the PLCOm2012 model performance in the Lahey
lung cancer screening participants using the screening program data base and Lahey clinical
medical records. All of the predictor variable data were available for the Lahey screening
program participants except for education. Dr. Martin Tammemagi provided a reparameterized
six year lung cancer risk prediction model, PLCOm2012noEd, without the education parameter
for this study (M. Tammemagi, PhD e-mail communication, September 4, 2015). The
reparameterized model was developed using the same data set used for development of
PLCOm2012.
Chapter 5: Methods
5.1 Study Design
This study is a review of the predictive capability of the PLCOm2012noEd, six year lung cancer
risk prediction model using data collected retrospectively from Lahey physician referred patients
enrolled in the Lahey Hospital & Medical Center lung cancer screening program between
January 1, 2012 and November 30, 2015. All patients met National Comprehensive Cancer
Network Clinical Practice Guidelines in Oncology: Lung Cancer Screening v1.2012 (NCCN
Guidelines®) high risk criteria for lung cancer (Table 1) and had a physician order for CT lung
screening. Patients were not eligible for screening if they had known metastatic disease, had
been diagnosed with lung cancer within the previous five years, or had symptoms concerning
for lung cancer. The CT lung screening program staff confirmed all participant eligibility at
program entry. The study was approved by both the Lahey Hospital & Medical Center and the
University of Connecticut Heath Center IRBs with a waiver of individual patient consent.
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Table 1 – National Comprehensive Cancer Network (NCCN) Group 1 and Group 2 Lung
Cancer Screening Criteria
NCCN Group 1 (n=
1715)

NCCN Group 2 (n=587)

Age

55 – 74

50 – 74*

Smoking History

≥ 30 pack years

≥ 20 pack years

Smoking Status

Current or former

Current or former

Quit Duration

< 15 years

Any time
At least one of the following required:

 Personal history of smoking related cancer
(excluding metastatic disease)
None required

Family history of lung cancer (parent, sibling,
Factors
or child)
 Personal history of chronic lung disease
 Occupational exposure to known lung
carcinogen(s)**
*>50 in NCCN Guidelines®; **Carcinogens include arsenic, asbestos, beryllium, cadmium, soot,
chromium, diesel fumes, nickel, silica, coal smoke, and radon (occupational or documented residential).
Additional Risk

5.2 Description of the Lung Cancer Screening Program Study Sample
The screening program sample included 2302 Lahey physician referred patients in the lung
cancer screening program between Jan 1, 2012 and November 30, 2015. Thirty five patients in
the program during this period were not included in the 2302 sample due to incomplete data. Of
those 35, one was removed due to lack of information on height in the medical record (needed
to calculate BMI) and 34 were removed due to declining to provide race and race not being
available in the medical record. Table 2 describes the screening program sample
demographics. The participants range from age 48 to 77 with a mean of 62.5 years. All
participants underwent a baseline scan (except for 3 participants in the program with a long
delay between program entry and their first scheduled screen). Mean duration in the program
was 1.86 years with a standard deviation of 1.04 years. In the screening program sample, 2269
(98.6%) of participants were white, 1205 (52.3%) current smokers, 1028 (44.7%) female, 538
(23.3%) had a 1st line relative diagnosed with lung cancer, 651 (28.3%) had a personal history
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of cancer and 1690 (73.4%) had COPD, chronic bronchitis or emphysema. There were 70 lung
cancers diagnosed. Eight (11.3%) lung cancers diagnosed were in participants in the first
quartile of PLCOm2012noEd model predicted six year risk of developing lung cancer, 14 (20%)
in participants in the second quartile, 19 (31.7%) in participants in the third quartile and 29
(41.43%) in participants in the fourth quartile (Figure1).
Table 2 – Lung Cancer Screening Program Study Sample Characteristics
Complete Group (n=2302)
Age (years)
62.5 ± 6.22
BMI
29.13 ± 5.90
Duration in Program (years)
1.86 ± 1.04
White Race
2269 (98.6%)
Years Smoked
37.03 ± 9.51
Avg Cigarettes smoked per day
26.6 ± 11.4
Years Quit (former smokers)
10.6 ± 9.0
Smokers
1205 (52.3%)
Female
1028 (44.7%)
NCCN Group 2
587 (25.5%)
COPD/Emphysema/Chronic Bronchitis
1690 (73.4%)
Personal History Cancer
651 (28.3%)
Family History Lung Cancer
538 (23.3%)
Lung Cancers Diagnosed
70 (3.0%/Annualized 1.6%)
Deaths (all causes)
27 (1.17%/Annualized 0.63%)
Values are reported as mean ± standard deviation.
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Figure 1 – Screening Program Diagnosed Lung Cancers by Quartile
Lung Cancer Risk Quartiles
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5.3 Data Sources and Collection
Patient data for the model predictor variables and screening program sample characteristics for
comparison to the model development sample was obtained from the sources shown in Table 3.
The data downloaded from the lung cancer screening program data base included the patient
responses to the lung cancer screening eligibility questions, age, sex, medical record number
(MRN), date of initial contact, dates of LDCT scans, LDCT scan results including indications for
lung cancer, extent if any of emphysema (mild, moderate, marked) and incidental findings.
A paper intake form (Figure 2) was used by the screening program personnel to determine
eligibility for screening when the patient called to schedule their CT scan. All patients were
asked the first 4 questions; a) age, b) smoking history; packs per day smoked and number of
years smoking, c) current smoking status and for former smokers time since quit, and d) if the
13

patient had a personal history of cancer including making sure no there was no history of lung
cancer in the previous 5 years. Pack years were calculated using the Smoking Pack Years online calculator.37 The data from the form was entered into the lung cancer screening data base.
For smoking history only current smoking status, years quit for former smokers and the
calculated pack years were entered into the data base. Average packs smoked per day and
number of years smoked were collected from the paper record intake forms for this study.
Table 3 – Screening Program Study Predictor Variable Data Sources
Predictor Variable

Description

Data Source

Age

Age in year at program entry

Screening Data Base

Race/Ethnicity

Self report: White/Black/Hispanic/Asian/Native Hawaiian or Pacific Islander
Kilograms/height in meters ^2 was calculated from the participant latest recorded height and weight in
BMI
the medical record.*
Family history of lung cancer was coded yes if either the participant self-reported a 1st line relative with
Family history of lung
lung cancer or there was a note in any of the medical records of a family history of lung cancer in a 1st
cancer
line relative
Participant self-reported history of cancer, any cancer including basal cell carcinoma, or the medical
Personal history of cancer record indicated any type of cancer diagnosis.
Participant self-reported COPD, emphysema or chronic bronchitis OR the medical record indicated a
diagnosis of COPD, emphysema or chronic bronchitis OR emphysema was noted on the radiologist
COPD
report for the baseline LDCT scan

EPIC Medical Record

Years smoked

Participant self-report

Paper intake forms

Years quit

Participant self-report

Screening Data Base

Duration

Time from the initial LDCT scan to November 30, 2015.**

Screening Data Base

Smoking status
Average number of
cigarettes smoked

Participant self-report

Screening Data Base

Participant self-report

Paper intake forms

EPIC Medical Record

Screening Data Base or EPIC Medical Record
Screening Data Base or EPIC Medical Record
Screening Data Base, EPIC Medical Record, or Radiologist
note of emphysema on initial LDCT scan

* If significant weight changes were noted in the medical records since the initial LDCT scan, weight
was obtained from a record closest in time to the initial LDCT scan (4 participants)
** Except for 3 participants in the program with first LDCT scans scheduled but not yet completed;
duration was calculated from program entry

If based on the answers to the first four questions, the patient met screening criteria for either
NCCN Group 1 (age, smoking history, time quit) or Group 2 (age, smoking history and had a
personal history of cancer), no further questions were asked. Patients who met the age and
smoking history criteria for NCCN Group 2 but did not have a personal history of cancer were
asked about the additional risk factors, one at a time until a risk was identified or until all the
questions were asked and answered (Figure 3). Since not all participants were asked all of the
questions, the data in the lung cancer screening data base for the predictor variables family
history of lung cancer and patient history of COPD were incomplete. The protocol for intake
screening was changed February 2, 2015 to ask all patients all of the questions and to enter the
number of packs per day average and number of years smoked into the data base in addition to
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pack years. Regardless of this change, the same protocol was used for data sources for all
patients in this study.
For screening program variables not available from the screening data base, patient medical
records in the Lahey EPIC system were examined (chart read). These records included
demographic information, physician notes, pathology reports, and imaging reports.

Figure 2 – Screening Program Intake Form
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Figure 3 – Screening Program – Follow-on Questions
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5.4 Data Coding for Missing or Uncertain Data
Sensitivity analysis was performed to assess the impact of missing and uncertain data on model
predictive capability as described in the next section (5.5 Statistical Analysis).
Participants with no response to family history of lung cancer in the lung cancer data base, or
who reported being adopted, not knowing their family history, or not having any family history on
file were coded as not having a family history of lung cancer. Participants with limited family
history in the medical files and no information on family history of lung cancer were coded as not
having a family history of lung cancer. These amounted to a total of 142 of 2302 participants:


22 adopted



75 NCCN Group 1 with limited family history



2 NCCN Group 2 with personal history of cancer and limited family history



43 with no family history on file in Group 1 or in Group 2 with a personal history of
cancer

Of note, as part of the intake process protocol described in the previous section, participants in
NCCN Group 2 who answered “no” to the question “Do you have a personal history of cancer?”
were then asked if they had a family history of lung cancer. These participants were considered
to be accurately coded as having no family history of lung cancer, even if they had limited or no
family history on file, because they were asked, and answered, the family lung cancer history
question. These participants are not included in the 142 described above. There are 17 of 2302
participants that met this criteria.
Participants with self-report of having a family history of lung cancer, contradicted by medical
record review, were coded according to patient self-report. Participants not asked the question
about family history of lung cancer with uncertainty around the family member with lung cancer
based on chart review, were coded as having a family history of lung cancer. There were 10 of
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2302 participants that met the first criteria and 13 of 2302 participants that met the second
criteria.
Participants with a family history of unspecified cancer were coded as no family history of lung
cancer. There were 71 of 2302 participants that met this criteria.
Participants with self-report of personal history of cancer, either yes or no, that was not
confirmed or was contradicted by medical record review, were coded according to patient selfreport. There were 14 of 2302 participants that met this criteria (4 coded as having a personal
history and 10 coded as not having a personal history of cancer).
5.5 Statistical Analysis
As this study assessed an existing lung cancer risk prediction model in a different sample, it was
important to delineate the differences between the samples used for model development and
validation and the study sample. The model also evolved through time so understanding the
differences in the models was important as well. As discussed in Chapter 4: Pedigree of the
Screening Program Study Model, the baseline model was developed in the PLCO sample, then
modified for the NLST sample criteria and then reparameterized for this study with the patient
education predictor variable removed.
The differences in the PLCO, NLST and the screening program study design, demographics,
screening scan frequency, data collection methods, and duration are described in Chapter 6:
Results. Comparisons of the predictor variables and the odds ratios for the predictor variables
for the PLCOm2011, PLCOm2012 and PLCOm2012noEd models are also described in Chapter
6. The PLCOm2012 and PLCOm2012noEd risk models were both run for the same individual
with a high risk of lung cancer. The predicted risk of lung cancer for the individual was
compared between the 2 models.

18

Demographic differences between the screening program sample, the model development
sample and the NLST sample were assessed pairwise using Pearson’s Chi-Square Test for
categorical variables and the independent samples T test (2 sided) for continuous variables.
The reparameterized lung cancer risk prediction model (without the education predictor variable)
provided by Dr. Martin Tammemagi (PLCOm2012noEd) was run for the complete Lahey
sample.
Assessment of the predictive capability of a risk prediction model includes assessments of both
discrimination and calibration. Discrimination is the ability of the model to identify the cases from
the non-cases; in this study the ability of the PLCOm2012noEd model to identify participants in
the screening program who will get lung cancer in the next six years from those that won’t.
Calibration is the ability of the model to accurately predict the level of risk that is observed. In
this study, the accurate prediction of the six year risk of getting lung cancer, or in other words,
how well did the number of observed lung cancers compare to the number of model predicted
lung cancers. Gail et al. found that discriminatory performance was more important than good
calibration in screening applications as compared to preventative interventions.38 However, both
calibration and discrimination are important for selecting the right individuals to screen.
Particularly important is having good model calibration around the threshold for screening
selection.26 This is especially true for lung cancer screening models as the predicted absolute
risk levels are small with peak frequency distributions close to the recommended screening
threshold risk level.30
The model predictive capability was assessed for the complete sample and for the NCCN Group
1 and Group 2 subgroups. Discrimination was assessed using the area under the receiver
operator curve (AUC). The receiver operator curve (ROC) is a plot of specificity and sensitivity
characteristics across the full model predicted risk threshold levels; specifically a plot of 1specificity (false positive rate) vs. sensitivity (true positive rate). An area under the curve (AUC)
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of 1.0 represents perfect discrimination and an AUC of 0.5 is no better than random chance.39
AUC’s >0.5 and < 0.7 are considered poor discrimination, 0.7 to < 0.8 good discrimination and
0.8 to < 0.9 excellent discrimination.26, 40 AUC’s in samples with different characteristics and
different follow-up times as compared to the development sample are likely to be lower than the
AUC for the development samples.26,39
The Hosmer-Lemeshow goodness-of-fit test was used to assess calibration. The test forms subgroups and compares predicted to observed risk. Typically 10 sub-groups are formed and the
average observed and average predicted risk in each decile are compared to each other. The
statistic follows a chi-squared distribution with degrees of freedom = number of subgroups – 2.39
A small p value (<0.05) is an indication of statistically significant differences in the risks and thus
poor calibration. In this study, the Hosmer-Lemeshow test compared the predicted risk of lung
cancer to the observed risk of lung cancer for 10 sub-groups. There have been criticisms of the
Hosmer-Lemeshow test over differences in test significance level for the same model/sample
based on grouping of the data.42 It is recommended to use the standard number of 10 groups
for consistency.42 For this study, in addition to the significance level of the test, the model
calibration was assessed graphically for each decile, as described below, to evaluate calibration
at the risk screening threshold, the area most important for good calibration in selection of
individuals to screen.
Because the model outcome is a binary variable (lung cancer yes or no), plotting risk vs.
outcome results in only 0 and 1 values for the outcome. A generally used graphical technique
for assessing model calibration is to use a smoothing algorithm, typically the lowess algorithm,
to estimate the probability of the predicted outcomes.39 I decided not to assess calibration
using the lowess algorithm for the screening program model outcomes because of the small
number of cases (70 yes lung cancers in 2302 complete sample). Instead, graphical
representations using the mean predicted risks and mean observed outcomes of the Hosmer20

Lemeshow test were used for graphical calibration assessments. These were plots of the
absolute value of observed – predicted mean risk by decile, predicted vs. observed mean risk
by decile and predicted vs. observed number of lung cancers by decile.
Additional assessments of model performance included evaluation of the difference and
statistical significance of mean risks between participants with and without lung cancer,
sensitivity and specificity in identifying lung cancer by risk percentile, and the lung cancer risk
probability distributions for participants with lung cancer as compared to participants without
lung cancer; especially around the screening risk threshold of 1.51%. Sensitivity, specificity and
PPV at the recommended screening risk threshold were evaluated for the complete sample and
for the NCCN Group 1 and NCCN Group 2 sub-groups. The difference and statistical
significance in model predicted risks and observed lung cancers between NCCN Group 1 and
Group 2 participants, the percentage of NCCN Group 1 and Group 2 participants that met the
1.51% screening threshold and the number of lung cancers identified in NCCN Group 1 and
Group 2 participants using this threshold were assessed.
For the sensitivity analysis the PLCOm2012noEd model was run for 5 separate scenarios as
detailed below to assess the impact on model performance of missing data, uncertain data, and
differences in model development and validation coding of present/absent conditions for
selected predictor variables.
The impacts on model predictive performance were assessed by comparing each of the
PLCOMm2012noEd model scenario results to the complete sample (baseline) model results for
the difference in mean risk and the statistical significance of the difference in mean risk for
participants with lung cancer vs. without lung cancer. Additionally, the AUC for the complete
sample model results and the model AUC for each of the five scenarios was compared.
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1. Reduced sample; participants that were adopted or participants that were not asked the
question “do you have a family history of lung cancer?” and had no or limited family
history on file were deleted from the baseline sample – 142 of 2302 participants were
deleted from the sample. Of these participants, one had lung cancer; the remaining 141
did not. This reduced the number of lung cancers in the sample from 70 to 69.
2. Complete sample with only patient self-reported history of cancer coded as patient
history of cancer. In other words, participants coded as “1” in the baseline sample for
personal history of cancer based solely on a medical record review indicating a
diagnosis of cancer were recoded to “0”, or no personal history of cancer. 224 of 651
patients were recoded from “1”, yes personal history of cancer to “0” no personal history
of cancer.
3. Complete sample with only patient self-reported history of cancer, excluding nonmelanoma skin cancer, coded as patient history cancer. 342 of 651 patients were
recoded from “1”, yes personal history of cancer to “0” no personal history of cancer.
4. Complete sample with only patient self-reported COPD, emphysema, or chronic
bronchitis coded as patient history COPD. In other words participants coded as “1” in the
baseline sample for history of COPD based only on; 1) a medical record review
indicating a diagnosis of COPD, emphysema or chronic bronchitis and/or 2) a report of
emphysema on the initial LDCT in the radiologist report were recoded to “0” no personal
history of COPD. 1241 of 1690 participants were re-coded from “1” yes history of COPD
to “0” no history of COPD.
5. Complete sample with family history of unspecified type of cancer, coded as “0”, no
family history of lung cancer, in the baseline now coded as “1”, yes family history of lung
cancer. 71 of 1764 participants were re-coded from “0” no family history of lung cancer
to “1” yes family history of lung cancer.
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The significance level was set at p ≤ 0.05 for all statistical analysis. All reported P values for the
independent T test are 2 sided. All data are reported as mean +/- standard deviation, range or
percentage as appropriate. All statistical analysis was performed using the statistical software
platform R version 3.1.2.43
Chapter 6: Results
6.1 Comparison Screening Program to PLCO and NLST
Table 4 summarizes the design for the screening program as compared to PLCO and NLST.
The PLCO study was a randomized population study with entrance criteria consisting primarily
of age and being cancer free. The NLST was a prospective randomized clinical trial while the
screening program study was a retrospective review of clinical data. Both the screening
program study population and the NLST required heavy smoking histories, minimum time since
quit for most, as well as age. The screening program study sample differs from the NLST in
including the NCCN Group 2 of younger, lighter smokers, with no minimum time quit and having
an additional risk factor for lung cancer.
Additionally, the screening program sample only had 1.86 years mean duration as compared to
eleven and six years for the PLCO and NLST samples (the PLCO sample for model
development was limited to 6 years), respectively. Both the PLCO and NLST studies included
non-screen detected lung cancers. Most of these were during the follow-up period after the
planned rounds of screening were completed. All of the screening program lung cancers were
screen detected. As discussed previously, in the screening program study, all participants had
an initial screen, T0, (except for 3 participants still in the program with a long delay between
program entry and their first scheduled screen). Not all screening program participants had
follow-on scans; 248 (10.8%) only had an initial screen, 1239 (53.8%) had a first annual screen
(T1), 635 (27.6%) had a second annual screen (T2) and 173 (7.5%) had a 3rd annual screen
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(T3). Only 4 participants had a 4th annual screen, T4 (0.17%). In comparison, in the PLCO and
NLST studies all participants completed the baseline, T0, and planned annual screens T1, T2,
and for PLCO, T3. The annual screens were administered at one year intervals for all
participants unless found to have lung cancer or other pathology that would preclude annual
screening. For the screening program study, annual scans were administered one year from the
last screening scan or from the last diagnostic scan follow-up for suspicious findings on an
exam whichever occurred last. The average time between T0 and T1 was 430 days or 1.2 years
PLCO data were collected via a self-reported survey at the beginning of the study and lung
cancer diagnoses were ascertained via annual study update forms and verified with medical
records.36 Similarly, for the NLST, the participants completed a questionnaire including
demographic and smoking behavior characteristics. Medical records were examined to
determine lung cancer diagnosis.5
Table 4 – Screening Program Comparison Summary

PLCO

Prospective, Randomized,
Population Study, 10 sites

Chest X-Ray vs Usual
Care

Number of Screens and
follow-up duration
4 annual screens T0, T1, T2, T3
(only T0,T1, and T2 for never
smokers), 11 year follow-up,
self-report in survey:
demographics and medical
Ages 55-74, any smoking history including nonhistory, medical record
smokers, no history colon, prostate, lung,
confirmation lung cancer
ovarian cancer
diagnosis.

NLST

Prospective, Randomized,
33 sites

Low Dose CT scan vs
Chest X-Ray

Ages 55-74, 30 or more pack years, less than 15
years quit, no history lung cancer within 5 years

Study

Study Type

Arms

Entry Criteria

3 annual screens T0, T1, T2, 6
year follow-up

Ages 55 to 74; 30 or more pack years and less
Retrospective review
than 15 years quit AND ages 50 to 74; 20 or more
clinical records, 2 sites in N/A - all screens Low
pack years, no criteria time quit with one
Baseline screen and continued
close proximity
Dose CT scan in clinical additional risk factor for lung cancer, no history annual screens, mean time in
Screening Program
geographically
practice
lung cancer within 5 years
program 1.84 years

Number of
Participants

77,464

53,454

2,302

Data sources

Self-report in survey:
demographics and medical
history, medical record
confirmation lung cancer
diagnosis.
Self-report survey:
demographics and medical
history, medical record
confirmation lung cancer
diagnosis
Self-report smoking history,
medical records review and
self-report demographics and
medical history, medical
record confirmation lung
cancer diagnosis.

6.2 Comparison of Lung Cancer Screening program Sample Characteristics to PLCO Model
Development Sample and NLST Sample
Table 5 compares the screening program sample characteristics to the PLCO sample used to
develop the PLCOm2012 model and to the NLST sample.13 Age is similar across all 3 studies
although the screening program sample is statistically older than the NLST sample (p<0.0001).
24

Family history of lung cancer is not statistically different between the screening program sample
and NLST, 23.4% vs. 22.1%, respectively (p=0.156). All of the remaining characteristics are
statistically significantly different between the screening program sample, and PLCO sample
and the screening program sample and NLST sample (p<0.0001).
The screening program participants were primarily white, 98.6%, as compared to 88.5% for
PLCO and 91.5% for NSLT. More than 25% of the screening program participants had a
personal history of cancer as compared to 4.7% and 4.3% in PLCO and NLST, respectively.
Almost three quarters of screening program participants had COPD as compared to 9.1% and
5.1% for PLCO and NLST, respectively. Smoking characteristics, although statistically
significantly different between the screening program sample participants and NLST, are more
similar to each other than to PLCO smoking characteristics. The screening program sample only
had 1.86 years mean duration as compared to six years for the PLCO and NLST (the PLCO
sample for model development was limited to first 6 years of the total 11 year follow-up).
The screening program coded any self-reported cancer, including basal cell skin cancer, as the
participant having a personal history of cancer. Additionally, participants were coded as having
a personal history of cancer if there was a cancer diagnosis in the medical record before the
initial LDCT scan, regardless of patient self-report. The NLST study survey questions only
asked about selected cancers; bladder, breast, cervical, colorectal, esophageal, kidney, larynx,
lung, nasal, oral, pancreatic, pharynx, stomach, thyroid and transitional cell cancers.44 PLCO
entrance criteria specified no prostate, lung, colorectal or ovarian cancer history. Also, in the
PLCO baseline survey, participants were asked to exclude basal cell carcinoma when
answering the question about ever being diagnosed with cancer.45
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Table 5 – Characteristics of Participants in the PLCO model development sample, the
NLST sample and the screening program sample
Variables
Sample size
Number of Lung Cancers
Age (years)
Sex
Female
Male
Race/Ethnicity
White
Black
Hispanic
Asian
Native American
Pacific Islander
Body mass index (kg/m2)
Personal History Cancer
No
Yes
Family history lung cancer
No
Yes
COPD
No
Yes
Smoking Status
Former
Current
Smoking Intensity (cig/day)
Smoking duration (years)
Smoking quit time - former
smokers (years)
Follow-up/Duration

PLCO Model
Dev't Sample
n=39,928
709
62.5 (5.3)
16816 (42.1%)
23112 (57.9%)

NLST Sample Lahey Sample
n=53,202
n=2302
1916
70
61.4 (5.0)
62.5 (6.22)
21811 (41%)
31391 (59%)

47864 (91.5%) 2269 (98.6%)
2331 (4.5%)
9 (0.4%)
661 (1.3%)
7 (0.3%)
1095 (2.1%)
15 (0.6%)
189 (0.4%)
2 (0.1%)
193 0.4%)
0 (0%)
28.0 (5.1)
29.1 (5.9)

38038 (95.3%)
1874 (4.7%)

50895 (95.7%) 1651 (71.7%)
2307 (4.3%)
651 (28.3%)

33906 (88.2%)
4523 (11.8%)

40880 (77.9%) 1764 (76.6%)
11608 (22.1%) 538 (23.4%)

35944 (90.9%)
3593 (9.1%)

50494 (94.9%) 612 (26.6%)
2689 (5.1%) 1690 (73.4%)

31985 (80.1%)
7924 (19.9%)
24.9 (14.7)
27.7 (13.8)

27590 (51.9%) 1097 (47.7%)
25612 (48.1%) 1205 (52.3%)
28.4 (11.5)
26.6 (11.4)
39.8 (7.3)
37.0 (9.5)
7.3 (4.8)
6.00

1.00
0.0164

<0.0001
0.0005

<0.0001

<0.0001

<0.0001
<0.0001

<0.0001
<0.0001

<0.0001

0.1558

<0.0001

<0.0001

<0.0001

0.0001

<0.0001
<0.0001

<0.0001
<0.0001

<0.0001
<0.0001

<0.0001
<0.0001

1028 (44.7%)
1274 (55.3%)

35308 (88.5%)
2234 (5.6%)
814 (2.0%)
1198 (3.0%)
242 (0.6%)
108 (0.3%)
27.4 (4.8)

20.2 (12.1)
6.00

P Lahey vs P Lahey vs
PLCO
NLST

10.6 (9.0)
1.86 (1.04)

Table data reformatted from: Tammemagi MC, Katkiha HA, Hocking WG, et al. Selection criteria for lungcancer screening, Supplement. N Engl J Med. 2013;368(8):728-236 DOI: 10.1056/NEJMoa1211776

In both the PLCO and NLST studies, COPD was self-reported in a baseline survey. Although
the definition of COPD includes both emphysema and chronic bronchitis,46 the NLST reported
all three of these as separate items. Combining the NLST survey results for COPD, emphysema
and chronic bronchitis results in 17.5% of the NLST sample having COPD.47 The PLCO
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baseline survey listed emphysema and chronic bronchitis as separate questions,48 while the
follow-on supplemental survey only listed emphysema.49 Participants in the screening program
were coded as having COPD if any one of the following criteria were met: self-report of COPD
during program intake interview, medical record review indicating a diagnosis of COPD,
emphysema, or chronic bronchitis, or report of emphysema on the radiologist report for the
baseline LDCT scan.50 The program intake interview protocol (previously discussed in Section
5.3 Data Sources and Collection) did not include asking all participants about a COPD
diagnosis, thus patient self-report of COPD data was biased and not feasible to use for model
evaluation.
Table 6 is a comparison of the screening program sample to the model development sample
and the NLST sample segregated by non-cases (no lung cancer) and cases (yes lung cancer).
The statistical significance of differences (p value) between the cases and non-cases for each
sample are shown. Both the model development and the NLST sample were statistically
significantly different between the cases and non-cases for essentially all of the listed
demographic and participant characteristics. In other words, in both the PLCO and NLST
samples people with lung cancer were significantly different from people without lung cancer for
all of the characteristics listed. Only sex was not significantly different for people with lung
cancer as compared to people without lung cancer for the NLST sample. For the screening
program sample, most characteristics between people with lung cancer and people without lung
cancer were not statistically significantly different. Only BMI and COPD were significantly
different between the cases and non-cases. People with lung cancer in the screening program
sample had lower BMIs than people without lung cancer and people with lung cancer were more
likely to have COPD than people without lung cancer.
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6.3 Comparison of Reparameterized study model, PLCOm2012noEd, to PLCOm2012 model
Table 7 compares the PLCOm2011, PLCOm2012 and PLCOm2012noEd logistic regression
models. The variables for PLCOm2012 and PLCOm2012noEd are the same except
PLCOm2012noEd does not include the education predictor variable. In PLCOm2012, four
variables are centered; age, education, smoking duration and smoking time quit. The 3 of these
variables that are included in PLCOm2012noEd are not centered. The difference in the model
constant accounts for differences due to centering. Comparison of odds ratios and p values
between the 2 models show they are similar with 5 of the 11 predictor variables being the same
to 2 significant digits (age, BMI, personal history of cancer, smoking duration, and smoking time
quit) and the others (race, COPD, family history of lung cancer, smoking status, and smoking
intensity) are the same between the models to the first significant digit.
The AUC for the reparameterized model, PLCOm2012noEd, in the development sample was
0.8007 (M. Tammemagi, PhD e-mail communication, September 4, 2015) as compared to an
AUC of 0.803 for PLCOm2012 in the same development sample.13
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Table 6 – Model Development, Screening Program, and NLST Sample Characteristics
Variables

PLCO Development data set
No Lung Cancer
Yes LC
Total
p
n= 39,219 (n=98.2%)
n=709 (n=1.8%)n=39,928 (100%)
62.4 (5.3)
64.6 (5.2)
62.5 (5.3)
<0.0001

Age (years)
Sex
Female
16545 (98.4%)
Male
22674 (98.1%)
Race/Ethnicity
White
34678 (98.2%)
Black
2181 (97.6%)
Hispanic
806 (99.0%)
Asian
1185 (98.9%)
Native American
241 (99.6%)
Pacific Islander
104 (96.3%)
Body mass index (kg/m2) 27.4 (4.8)
Personal History Cancer
No
37385 (98.3%)
Yes
1818 (97.0%)
Family history lung cancer
No
33365 (98.4%)
Yes
4393 (97.1%)
COPD
No
35388 (98.5%)
Yes
3451 (96.1%)
Smoking Status
Former
31600 (98.8%)
Current
7600 (95.9%)
Smoking Intensity (cig/day)
24.8 (14.7)
Smoking duration (years) 27.5 (13.8)
Smoking quit time former smokers (years) 20.3 (12.1)

Lahey data set
No Lung Cancer
n=2232 (97.0%)
62.5 (6.2)

Yes LC
n=70 (3.0%)
63.8 (7.2)

Total
n=2302
62.5 (6.22)

271 (1.6%)
438 (1.9%)

16816 (42.1%)
23112 (57.9%)

0.035

996 (96.9%)
1236 (97.0%)

32 (3.1%)
38 (3.0%)

1028 (44.7%)
1274 (55.3%)

630 (1.8%)
53 (2.4%)
8 (1.0%)
13 (1.1%)
1 (0.4%)
4 (3.7%)
26.5 (4.5)

35308 (88.5%)
2234 (5.6%)
814 (2.0%)
1198 (3.0%)
242 (0.6%)
108 (0.3%)
27.4 (4.8)

0.01

2199 (96.9%)
9 (100%)
7 (100%)
15 (100%)
2 (100%)
0 (0%)
29.2 (5.9)

70 (3.1%)
0 (0%)
0 (0%)
0 (0%)
0 (0%)
0 (0%)
27.2 (5.2)

653 (1.7%)
58 (3.0%)

38038 (95.3%)
1874 (4.7%)

<0.001

1604 (97.2%)
628 (96.5%)

541 (1.6%)
130 (2.9%)

33906 (88.2%)
4523 (11.8%)

<0.001

556 (1.5%)
142 (3.9%)

35944 (90.9%)
3593 (9.1%)

385 (1.2%)
324 (4.1%)
30.2 (15.2)
39.9 (10.5)
12.4 (10.5)

p

NLST data set
No Lung Cancer
n=51,286 (96.4%)
0.1314 61.3 (5.0)

Yes LC
Total
p
n=1916 (3.6%) 53,202 (100%)
63.7 (5.3)
61.4 (5.0)
<0.0001
774 (3.5%)
1142 (3.6%)

21811 (41%)
31391 (59%)

2269 (98.6%)
9 (0.4%)
7 (0.3%)
15 (0.6%)
2 (0.1%)
0 (0%)
29.1 (5.9)

0.9532 21037 (96.5%)
30249 (96.4%)
0.902
46125 (96.4%)
2233 (95.8%)
650 (98.3%)
1063 (97.1%)
180 (95.2%)
188 (97.5%)
0.003 28.0 (5.1)

1739 (3.6%)
98 (4.2%)
11 (1.7%)
32 (2.9%)
9 (4.8%)
5 (2.6%)
26.9 (4.7)

47864 (91.5%) 0.01
2331 (4.5%)
661 (1.3%)
1095 (2.1%)
189 (0.4%)
193 0.4%)
28.0 (5.1)
<0.0001

47(2.8%)
23 (3.5%)

1651 (71.7%)
651 (28.3%)

0.466 49105 (96.5%)
2181 (94.5%)

1790 (3.5%)
126 (5.5%)

50895 (95.7%) <0.001
2307 (4.3%)

1713 (97.1%)
519 (96.5%)

51 (2.9%)
19 (3.5%)

1764 (76.6%)
538 (23.4%)

0.539 39494 (96.6%)
11111 (95.7%)

1386 (3.4%)
497 (4.3%)

40880 (77.9%) <0.001
11608 (22.1%)

<0.001

606 (99.0%)
1626 (96.2%)

6 (1.0%)
64 (3.8%)

612 (26.6%)
1690 (73.4%)

0.00088 48770 (96.6%)
2497 (92.9%)

1724 (3.4%)
192 (7.1%)

50494 (94.9%) <0.001
2689 (5.1%)

31985 (80.1%)
7924 (19.9%)
24.9 (14.7)
27.7 (13.8)

<0.001
<0.0001
<0.0001

1063 (96.9%)
1169 (97.0%)
26.5 (11.3)
37.0 (9.5)

34 (3.1%)
36 (3.0%)
28.2 (12.1)
37.8 (9.1)

1097 (47.7%)
1205 (52.3%)
26.6 (11.4)
37.0 (9.5)

0.973 26826 (97.2%)
24460 (95.5%)
0.308 28.4 (11.5)
0.49 39.7 (7.3)

764 (2.8%)
1152 (4.5%)
29.6 (11.7)
44.2 (7.0)

27590 (51.9%) <0.001
25612 (48.1%)
28.4 (11.5)
<0.0001
39.8 (7.3)
<0.0001

20.2 (12.1)

<0.0001

10.6 (9.0)

8.9 (8.0)

10.6 (9.0)

0.209 7.3 (4.8)

6.6 (4.8)

7.3 (4.8)

<0.0001

0.6

<0.0001

Predictive Performance
Lung cancer incidence
per 10,000 per year in
former, current smokers
Mean lung cancer
probability
0.0169
AUC (95% CI)
0.803 (0.788 - 0.817)
Follow-up duration
(years)
6.00

20.7, 72.4
0.0453

169.4, 158.1
0.0174 <0.0001

0.03552
0.63 (0.57 - 0.69)
1.86

0.04556

0.03582

48.0, 79.9
0.02648

0.0316
0.701 (0.689 - 0.712)

0.0519

0.0323 <0.0001

6.00

Table data reformatted from: Tammemagi MC, Katkiha HA, Hocking WG, et al. Selection criteria for lung-cancer screening, Supplement. N Engl J
Med. 2013;368(8):728-236 DOI: 10.1056/NEJMoa1211776
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Table 7 – Model Comparisons; PLCOm2011, PLCOm2012, PLCOm2012noEd

Predictor variables

PLCOm2011

p

Age, per year
Age spline 1
Age spline 2
Age spline 3

1.245 (1.130 TO 1.3720 <0.001
0.705 (0.505 to 0.9840
0.04
2.205 (0.860 to 5.651)
0.1

Education, per 1 of 7
levels change

0.928 (0.887 to 0.9710

Race or ethnic group
White
Black
Hispanic
Asian
Native Hawaiian or
Pacific Islander

Smoking intensity
Model constant

p

PLCOm2012noEd

1.08 (1.057 to 1.105) centered age 62 <0.001 1.080 (1.055 to 1.104)

0.001

0.922 (0.874 to 0.972)

centered on level
4 of 6 levels
0.003

p

<0.001

n/a

n/a
1.000
1.484 ( 1.083 to 2.033)
0.475 (0.195 to 1.160)
0.627 (0.332 to 1.185)

0.01
0.1
0.15

1.000
referent group
1.563 (1.144 to 2.134)
0.005
0.501 (0.205 to 1.221)
0.128
0.627 (0.332 to 1.184)
0.15

2.793 (0.992 to 7.862)

0.05

2.763 (1.018 to 7.769)

0.054

0.001

0.973(0.955 to 0.991)

0.003 0.975 (0.957 to 0.993)

0.006

0.001

1.799 (1.471 to 2.200)

<0.001 1.815 (1.484 to 2.219)

<0.001

0.001

1.582 (1.172 to 2.128)
1.427 (1.162 to 1.751)

0.003 1.578 (1.168 to 2.131)
0.001 1.451 (1.182 to 1.781)

0.003
<0.001

1.117 (1.019 to 1.225)

0.019

n/a

n/a

n/a

n/a

1.059 (1.044 to 1.074)
0.949 (0.935 to 0.964)

<0.001
<0.001

1.012 (0.995 to 1.029)

0.171

BMI per 1 unit change 0.972 (0.956 TO 0.988)
Family history of lung
cancer, yes vs no
1.561 (1.313 TO 1.856)
Personal histoy of
cancer
n/a
COPD, yes vs no
1.374 (1.145 TO 1.6480
Chest x-ray in past 3
years per 1 of 3 levels
Pack-years smoked
per 1 pack year
Pack- year spline 1
Pack-year spline 2
Smoking duration per
1 year increase
Smoking quit time in
smokers per 1 year
quit
Quit time spline 1
Quit time spline 2
Smoking status
Former
Current

PLCOm2012

0.945 (0.918 to 0.974)
1.047 (1.011 to 1.085)

<0.001
0.01

referent
1.356 (1.077 to 1.708)

0.01

referent group

1.032 (1.014 to 1.051)

centered on 27
years

0.001 1.035 (1.016 to 1.054)

<0.001

0.970 (0.950 to 0.990)

centered on 10
years

0.003 0.972 (0.951 to 0.992)

0.007

0.02

0.011

referent
1.297 (1.047 to 1.605)
((avg# cigperday/10)^1)-0.402154613

transformed
variable

-4.533

referant
1.319 (1.066 to 1.632)
((avg# cigperday/10)^- transformed
1)-0.402154613
variable
-9.508

Table data reformatted from:
Tammemagi CM, Pinsky PF, Caporaso PA, et al. Lung Cancer Risk Prediction: Prostate, Lung, Colorectql and
Ovarian Cancer Screening Trial Models and Validation. J Natl Cancer Inst. 2011;103(13):1058-1068. Doi:
10.1093/jnci/djr173.
Tammemagi MC, Katkiha HA, Hocking WG, et al. Selection criteria for lung-cancer screening. N Engl J Med.
2013;368(8):728-236 DOI: 10.1056/NEJMoa1211776
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Figures 4a and 4b show a comparison of the baseline model, PLCOm2012, (Figure 4a) to the
PLCOm2012noEd model (Figure 4b) for a 69 year old former smoker, 11 years quit, with
COPD, a family history of lung cancer and a heavy smoking history. The calculated risk of lung
cancer is similar for the 2 models; 6.9% for the PLCOm2012 model and 6.15% for the
PLCOm2012noEd model. The equivalent “entry” risk level to meet the USPSTF criteria for lung
cancer screening is 1.3455%,13 so this individual is at high risk for lung cancer. In fact, this
individual is my late husband who was diagnosed with Stage 4 lung cancer in October 2011 and
died in April 2013. He is a good example of how the model individual predicted six year risk of
developing lung cancer would have provided additional information, beyond just meeting the
USPSTF/CMS risk screening criteria, to help with the screening decision. His risk was well
above the screening risk threshold indicative of a high risk of lung cancer and a higher likelihood
of benefiting from lung cancer screening than someone who met the guidelines but with a model
predicted six year risk of lung cancer closer to the screening risk threshold.
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Figure 4a – PLCOm2012 Six Year Probability of Lung Cancer
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Figure 4 b – PLCOm2012noED Six Year Probability of Lung Cancer

6.4 Model Predictive Performance in the Screening Program Sample
The PLCOm2012noEd model six year mean risk for lung cancer was higher for participants with
lung cancer, 4.56%, as compared to those without lung cancer, 3.55% (p=0.0265) (Figures 5
and 6). Area under the curve (AUC) of the receiver operator characteristics curve (ROC) was
0.63 (95% CI 0.57 – 0.69) (Figure 7). The mean absolute difference between observed and
predicted risk was 0.013 or less for the first 9 deciles (Figure 8).
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The Hosmer-Lemeshow goodness of fit test p value was less than 0.05 (p= 0.0053) indicating
poor calibration (Figure 9). The large difference between the observed risk of lung cancer
compared to the PLCOm2012noEd model predicted six year risk of lung cancer above the 9th
decile drove the poor calibration result. The model predicted risk of lung cancer at the 10th
decile was 12.1% as compared to an observed risk of 3%; the predicted number of lung cancers
in the 10th decile was about 28 with only 7 lung cancers observed in this decile (Figures 10 and
11). Accurately capturing the extremes of a distribution is one of the limitations of the HosmerLemeshow test and was evident in this analysis.40
Figure 5 - Model Predicted Lung Cancer Risk in Screening Program Sample vs Lung
Cancers Diagnosed (p=0.0265)

34

Figure 6 – Box Plot Model Predicted Risk for Group with Lung Cancer and Group without
Lung Cancer (p=0.0265)

Figure 7 – Area Under the Receiver Operating Curve (AUC) is 0.63 (95% CI 0.57 – 0.69)
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Figure 8 – Mean Absolute Difference Between Observed and Predicted Risk; 0.013 or
Less in the First 9 Deciles of Screening Program Sample

PLCO data reformatted from: Tammemagi MC, Katkiha HA, Hocking WG, et al. Selection criteria for lungcancer screening, Supplement. N Engl J Med. 2013;368(8):728-236 DOI: 10.1056/NEJMoa1211776
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Figure 9 – Hosmer-Lemeshow Test; Observed vs Predicted Risk – 10 Sub-Groups
(p=0.0053)

Figure 10 - Predicted and Observed Lung Cancer Risk by Percentile
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Figure 11- Number of Lung Cancers Predicted vs Observed by Percentile
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Table 8 shows PLCOm2012noEd model sensitivity, specificity, positive predictive value (PPV),
negative predictive value (NPV), number of true positives, false positives, true negatives and
false negatives for a range of cut-off model predicted screening risk thresholds. At the lowest
levels of model predicted risk, the sensitivity was high because all lung cancers were identified.
However, the model specificity was the lowest as all of the non-lung cancers were false
positives. At the higher levels of model predicted risk, sensitivity was lower, not all lung cancers
were found, but the specificity was higher and there were fewer false positives. Tammemagi et
al. recommended a model predicted risk threshold to screen of 1.51% (based on NLST mortality
outcomes).30 At this recommended risk threshold, the PLCOm2012noEd model sensitivity in
the screening program sample was 85.7% with a specificity of 29.7%; the model PPV was 3.7%
and the NPV was 98.5%. The sensitivity of 85.7% indicated that almost 86% of people who
developed lung cancer met or exceeded the model screening predicted risk threshold or the
corollary, about 15% of people who developed lung cancer were below the model predicted
screening risk threshold. The low specificity of 29.7%, a result of the large number of false
positives (1569), indicated the selected model predicted screening risk threshold was poor at
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identifying participants that did not develop lung cancer. The low PPV indicated only 3.7% of the
participants that met the 1.51% risk screening threshold developed lung cancer despite having a
model predicted risk that exceeded the screening threshold. This is similar to the PPV of 4.2%
for the PLCOm2012 model in the validation sample. Although the PPV and specificity are low, in
the case of lung cancer screening, having a small percentage of false negatives (people who
develop lung cancer who are not identified as high risk) is important to reduce lung cancer
mortality.
Table 8 – Sensitivity and Specificity at Screening Risk Threshold (1.51%) 85.7% and
29.7%, Respectively
Cut off risk value
0.00%
0.89%
1.00%
1.21%
1.37%
1.51%
1.89%
2.38%
3.53%
4.41%
7.88%
50.53%

Percentile of risk
0.00
10.00
13.51
20.00
25.00
29.20
40.00
50.00
60.00
75.00
90.00
100.00

Patients at risk True positives
2302
70
2071
68
1991
68
1841
65
1726
62
1629
60
1381
54
1151
48
920
43
575
29
231
7
0
0

False positives
2232
2003
1923
1776
1664
1569
1327
1103
877
546
224
0

False negatives True negatives
0
0
2
229
2
309
5
456
8
568
10
663
16
905
22
1129
27
1355
41
1686
63
2008
70
2232

Sensitivity
1.000
0.971
0.971
0.929
0.886
0.857
0.771
0.686
0.614
0.414
0.100
0.000

Specificity
0.000
0.103
0.138
0.204
0.254
0.297
0.405
0.506
0.607
0.755
0.900
1.000

PPV
0.030
0.033
0.034
0.035
0.036
0.037
0.039
0.042
0.047
0.050
0.030
-

NPV
0.991
0.994
0.989
0.986
0.985
0.983
0.981
0.980
0.976
0.970
0.970

Comparison of the risk frequency distribution (percent of group) for participants with lung cancer
as compared to participants without lung cancer (Figure 12), shows the highest frequency for
both groups was at approximately 2%. This is above the 1.51% screening risk threshold. The
frequency decreased quickly for participants without lung cancer, to only 0.05% of the group by
6% predicted risk. The frequency for participants with lung cancer only decreased to 1.3% at
this same predicted risk. Between 4% and 8% predicted risk, participants with lung cancer were
a higher percent of their group as compared to participants without lung cancer.
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Figure 12 - Lung Cancer Risk Frequency Probability Distribution as Percent of Group
Model Predicted Lung Cancer Risk Probability Distribution
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6.5 Model Predictive Performance NCCN Group 1 vs Group 2
Lung cancer mean risk for the subgroup of NCCN Group 2 was significantly lower (p<0.0001)
than for NCCN Group 1; 1.84% vs. 4.18% (Figure 13). However, the percentages of lung cancer
were the same in both groups. Out of 70 cancers, 53 occurred in the 1715 Group 1 participants
(3.1%) as compared to 17 in the 587 Group 2 participants (2.9% ), p=0.9224.
Of the 587 NCCN Group 2 participants, 262 had predicted risk above the 1.51% recommended
screening threshold (44.6% of the Group 2 sample). Eleven of the 17 lung cancers were in
those with risk levels above 1.51%. The sensitivity and specificity of the model for this group at
the screening threshold were 64.7% and 56.0%, respectively. PPV was 4.2%. The sensitivity for
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this group was much lower than for the complete sample. Almost 40% of the people who
developed lung cancer were below the model predicted screening risk threshold.
For NCCN Group 1, 1368 of 1715 participants were above the 1.51% screening risk threshold
(79.8% of the Group 1 sample). Forty nine of the 53 lung cancers were in those with risk levels
above 1.51%. Sensitivity, specificity, and PPV were 92.5%, 20.6% and 3.6%, respectively. This
sub-group had the highest sensitivity at the model predicted screening risk threshold.
Figure 13 – Model Predicted Lung Cancer Risk NCCN Group 1 vs NCCN Group 2

6.6 Model Predictive Performance in NCCN Group 1
In the NCCN Group 1 subgroup (similar criteria as the NLST), the mean predicted risk for
participants with lung cancer was 5.249% as compared to 4.144% for those without lung cancer;
p=0.0424 (Figure 14).
Model AUC was improved to 0.641 (95% CI 0.576 – 0.706) (Figure 15).
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The Hosmer-Lemeshow goodness of fit test indicated poor calibration (p=0.0179), and showed
similar large observed to predicted lung cancer risk differences for the 10th decile as did the
complete sample (Figure 16). The 10th decile predicted risk of lung cancer was 13.3% as
compared to 2.9% observed risk (Figure 17). Similar to the complete sample, the number of
predicted lung cancers for the 10th decile was much larger than the number observed, 22.7 vs. 5
lung cancers, respectively (Figure 18).
Figure 14 – Model Predicted NCCN Group 1 Lung Cancer Risk in Screening Program
Sample vs Lung Cancers Diagnosed (p=0.0424)
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Figure 15 – NCCN Group 1 Area Under the Receiver Operating Curve (AUC) is 0.641 (95%
CI 0.576 – 0.706)

Figure 16 – NCCN Group 1 Hosmer-Lemeshow Test; Observed vs Predicted Risk – 10
Sub-Groups (p=0.0179)
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Figure 17 – NCCN Group 1 Predicted and Observed Lung Cancer Risk by Percentile
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Figure 18 – NCCN Group 1 Number of Lung Cancers Predicted vs Observed by Percentile
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6.7 Model Predictive Performance in NCCN Group 2
In the NCCN Group 2 subgroup (younger, lighter smoking history, no limit on time quit and one
additional risk factor ) the mean predicted risk for participants with lung cancer was 2.394% as
compared to 1.826% for those without lung cancer, but the difference was not statistically
significant; p=0.2507 (Figure 19).
Model AUC was 0.634 (95% CI 0.522 – 0.746) (Figure 20).
The Hosmer-Lemeshow goodness of fit test indicated poor calibration (p=0.0271) and exhibited
more variation between observed and predicted risk across the range of deciles as compared to
the complete sample (Figure 21).

Figure 19 – NCCN Group 2 Model Predicted Lung Cancer Risk vs Lung Cancers
Diagnosed (p=0.0265)
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Figure 20 - NCCN Group 2 Area under the Receiver Operating Curve (AUC)
is 0.634 (95% CI 0.522 – 0.746)

Figure 21 - NCCN Group 2 Hosmer-Lemeshow Test; Observed vs Predicted Risk – 10
Sub-Groups (p=0.0271)
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6.8 Sensitivity Analysis
The PLCOm2012noEd model was run for five modified codings of predictor variables and/or
modified samples to assess the impact of missing data, uncertain data and differences in
predictor variable data collection between the model development and the screening program
samples. Table 9 summarizes the results. The “Base case” in the table shows the original
analysis with the complete sample.
Table 9 – Sensitivity Analysis Results

Case Description
Base case
Remove adopted, no and limited family
history
Only patients self-reported with cancer
coded as 1 – personal history of cancer;
i.e. patient history of cancer based on
chart read only coded as 0 – 427
patients with cancer self-reported
(18.5%)
Only patients self-reported with cancer
other than only skin cancer coded as 1
for personal history of cancer – 309 pts
self-reported and with skin cancers only
excluded (13.4%)
With only patient reports coded as
positive for COPD
71 participant family history of lung
cancer changed from code 0 to code 1 –
these are participants with family history
of cancer – type not specified in medical
records

Sensitivity Studies
Mean risk
Mean risk (No (Yes lung
Difference
Sample size Lung Cancer)
cancer)
in means
2302

95% CI

P value

AUC

3.552

4.556

-1.004

-1.888 to -0.121

0.0265

0.63 (0.569-0.69)

3.561

4.589

-1.028

-1.922 to -0.133

0.0205

0.631(0.57-0.692)

2302

3.367

4.343

-0.976

-1.866 to -0.085

0.03216

0.621(0.56-0.683)

2302

3.268

4.119

-0.851

-1.594 to -0.107

0.02554

0.623(0.561-0.684)

2302

2.847

3.415

-0.568

-1.1788 to 0.0426

0.06779

0.623(0.564-0.681)

2302

3.641

4.788

-1.147

-2.081 to -0.212

0.01687

0.633 (0.572-0.694)

2160

To investigate the impact of missing family history information, the 142 participants that were
adopted or participants that were not asked the question “do you have a family history of
lung cancer?” and had no or limited family history on file were deleted from the screening
program baseline sample. The mean predicted risk of lung cancer for cases and non-cases
remained essentially the same as the baseline, as did the difference in means. The
difference in means remained statistically significant; p=0.0205. AUC was essentially
unchanged at 0.631 (95% CI 0.57-0.692).
To assess the sensitivity of the analysis to the data sources used to code a person as
having a personal history of cancer between the PLCOm2012noEd model development and
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validation samples and the screening program (self-report compared to self-report and
medical record note), the complete screening program sample was recoded with only
participant self-reported cancer coded as a personal history of cancer. This reduced the
percentage of participants in the screening program sample with a personal history of
cancer from 28.3% to 18.5%. The mean risk for both participants with and without lung
cancer decreased slightly (0.213 and 0.185, respectively). The difference in mean risk
between the cases and non-cases was still significant at p=0.03216. AUC was reduced
slightly to 0.621 (95% CI 0.56-0.683).

To further assess the sensitivity for the differences in the type of cancer that qualified for a
personal history of cancer between the model development and validation sample and the
screen program sample, the complete screening program sample with only patient selfreported cancer, excluding non-melanoma skin cancers, were coded as a personal history
of cancer. This reduced the percentage of participants with a personal history of cancer
further, from 18% to 13.4%. This was still about three times the percentage of personal
history of cancer as compared to both the PLCO and NLST samples. Mean risk declined
both for participants with and without lung cancer (0.437 and 0.284, respectively) and the
difference in the means remained statistically significant at p=0.02554. The AUC was 0.623
(95% CI 0.561- 0.684).

Similarly, to assess the sensitivity of the analysis results to the data sources used to code a
person as having COPD between the model development and validation and the screening
program sample, only patient self-reported COPD were coded as patient history of COPD
for the complete screening program sample. This reduced the percentage of participants
with COPD from 73.4% to 19.5%. The 19.5% of participants with COPD with the recoding
was still about double and triple the rates in the PLCO and NLST samples, respectively.
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Recall this was a biased sample in the screening program as not all participants were asked
the question about COPD during program intake. The mean risk in participants without lung
cancer was the lowest of all of the samples run at 2.847% (-0.705). Similarly, the mean risk
for participants with lung cancer was also reduced to the lowest of the samples; 3.415
(-1.141). Additionally, the difference between the mean risks was about half of what it was
for the baseline (0.568 vs. 1.004) and was no longer statistically significant at a p</= 0.05
level (p=0.06779) but still suggestive of a difference between participants with lung cancer
and those without lung cancer. AUC was reduced from 0.63 (95% CI 0.569-0.69) to 0.623
(95% CI 0.564-0.681).

To investigate the impact of a family history of an unspecified type of cancer that may have
been lung cancer, the family history for those with an unspecified cancer, coded as “0, no
family history of lung cancer, in the baseline analysis were recoded as “1”, yes family history
of lung cancer. There were 71 participants recoded. There was a slightly increased mean
risk for both participants with and without lung cancer, +0.890 and +0.232, respectively to
3.641% and 4.788% mean risk levels. The difference in the mean risk between cases and
non-cases was statistically significant, p=0.01687. AUC increased slightly to 0.633 (95% CI
0.572-0.694)
.
Chapter 7: Discussion
7.1 Overall Model Predictive Performance
This study is the first to assess a lung cancer risk prediction model in a clinical lung cancer
screening program. Model predictive performance included assessing both discrimination and
calibration. The predictive capability of the reparameterized PLCOm2012 model,
PLCOm2012noEd, in the screening program sample was not as good as in the model
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development sample and not as good as the PLCOm2012 model in the PLCO smoker control
and intervention group samples used for model development and validation, respectively. This
is expected as models perform best in their development data sets and lose predictive capability
in different samples.26
The PLCOm2012 model in the development and validations samples had AUC values
considered to be excellent and good discrimination, respectively.26,39 The PLCOm2012noEd
model AUC value was considered to be in the excellent discrimination range in the development
sample. In the screening program sample, the AUC was in the poor discrimination range. This is
not surprising as the model was developed and validated independently in different samples
with significant differences in sample characteristics from the screening program sample. A loss
in discrimination in a new and different sample for a model is to be expected even in samples
with similar characteristics as models perform best in the sample used to develop them; the
model coefficients are fit to the random variation specific to that sample.26 One of the major
differences in the samples likely to have impacted discrimination was the difference in follow-up
duration. The development and validation samples had six years of follow-up for every
participant vs. an average of 1.86 years of follow-up for the screening program participants. It is
likely this difference contributed to the lower model AUC scores as some of the non-cases (no
lung cancer) in the screening program are likely to become cases (yes lung cancer) with longer
follow-up.
The screening program sample included participants with as few as 1 day of follow-up. Deleting
screening program participants with fewer than 90 days of follow-up after a scan (127
participants and 2 lung cancers) and re-running the model did not significantly change the
results. The PLCOm2012noEd model six year mean risk for participants with lung cancer was
4.51% as compared to 4.56% for the complete sample. The mean risk for those without lung
cancer was 3.57% as compared to 3.55% for the complete sample. Area under the curve (AUC)
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of the receiver operator characteristics curve (ROC) was 0.622 (95% CI 0.56 - 0.684) as
compared to 0.63 (95% CI 0.57 – 0.69) for the complete sample.
There was also a significant difference in the sample size and number of cases (lung cancers)
between the model development and the screening program samples. The percentage of cases
was actually higher in the screening program as compared to the model development sample,
3.0% vs. 1.8%, respectively (Table 6), however, the number of cases (lung cancers) in the
screening program sample was still only approximately 10% of the number in the development
and validation samples (70 vs. 709 and 753 cases, respectively). Having fewer cases makes it
more difficult for the model to discriminate between a case and a non-case. Increased sample
size and/or longer duration follow-up would be required to increase the number of cases in the
sample.
Although the Hosmer-Lemeshow goodness-of-fit test indicated poor calibration with p=0.0053,
the area of poor calibration was in the 10th and top decile of risk, well above the screening risk
threshold. The absolute error between the mean predicted and observed probability of lung
cancer in the 3rd and 4th deciles (encompass the 1.51% screening risk threshold) was 0.008 and
0.009, respectively and comparable to the PLCOm2012 model in the PLCO data sample at
0.007 and 0.010. (Figure 7). These indicate good calibration around the screening selection risk
threshold.
Sensitivity was also indicative of good model performance. Specificity, and PPV were both low
indicating a large number of false positives, i.e. people meeting the screening threshold but not
developing lung cancer. In the case of lung cancer screening, high sensitivity is required to
reduce lung cancer mortality.4 CMS and USPSTF guidelines and clinical practice for lung
cancer screening include management of false positives to minimize the potential harms of
screening.9,10,51 The sensitivity, specificity and PPV for the PLOCm2012noEd model in the
screening program sample at the 1.51% screening risk threshold were 85.7%, 29.7% and 3.7%,
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respectively. These compare favorably to the PLCOm2012 model in the PLCO validation
sample for sensitivity (80.1%) and are worse for specificity (66.2%) and slightly worse for PPV
(4.2%).30
The PLCOmnoEd model was fairly good at predicting lung cancers in this independent sample
especially given; 1) the differences in the samples; sample size, personal cancer history and
COPD prevalence, lack of race diversity; 2) the differences in the study designs; retrospective
vs. prospective and the 1.86 years average follow-up vs. 6 years.
From a clinical perspective, use of the PLCOm2012noEd model (or prospectively PLCOm2012)
will not replace use of the USPSTF and CMS criteria for lung cancer screening participant
selection. The immediate value of the risk model will be in helping both the participant and the
ordering physician assess the individualized risk and aid in the shared decision making
discussion required by CMS for reimbursement. Knowing that the model has fair predictive
capability, especially at the recommended screening threshold criteria will increase confidence
in use of the model.
7.2 Model Performance for NCCN Group 1 and NCCN Group 2
The PLCOm2012noEd predictive performance for the sub-group of 1715 participants meeting
the criteria for NCCN Group 1, essentially the NLST criteria, had slightly improved discrimination
and similar calibration as for the complete sample.
However, the model did not discriminate well between participants with lung cancer and
participants without lung cancer in NCCN Group 2.
Group 2 participants had significantly lower model predicted risk of lung cancer as compared to
NCCN Group 1 (p<0.0001). Additionally, the model predicted mean risk between participants
with lung cancer in NCCN Group 2 was not significantly different from those without lung
cancer. However, the observed prevalence of lung cancer for the 2 groups was not
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distinguishable between the two groups (p=0.9274). This may indicate the lack of a significant
predictor variable for this group. PLCOm2012noEd includes all of the additional qualifying risk
factors for NCCN Group 2 (COPD, family history of lung cancer, personal history of cancer)
except for exposure to occupational carcinogens (radon, asbestos, arsenic, cadmium, and
diesel fumes). This exposure predictor variable was not consistently available for the screening
program participants, but at least 1.8% in the complete sample are known to have exposure. A
subgroup of screening program participants (228) were asked about their occupational
carcinogen exposure during program intake. Thirty six of the 228 of participants asked the
question (15.8%) indicated an occupational exposure. Thus it is likely the percentage in the
complete sample, if all had been asked the question about exposure, would have been larger
than 1.8%. The program intake protocol now requires asking all participants about exposure at
every annual screening LDCT.
Another risk factor for lung cancer that was not one of the PLCOm2012noEd predictor variables
is having more than one relative diagnosed with lung cancer. This may have impacted the
NCCN Group 2 predicted risk relative to observed risk. A systematic review of the relationship
between family history and lung cancer found an increased risk of lung cancer when multiple
family members had lung cancer as compared to only one; RR 1.57% (95% CI 1.34 – 1.84) for
one family member as compared to RR 2.52% (95% CI 1.72-3.70) for having two or more family
members impacted by lung cancer.52 Although PLCOm2012noEd included a family history of
lung cancer as one of the prediction variables, there was no distinction between having one
versus multiple family members diagnosed with lung cancer. In NCCN Group 2, 5.1% of
participants (30 of 587) had more than one family member diagnosed with lung cancer while
only 2.1% of NCCN Group 1 participants (36 of 1715) had more than one family member
diagnosed with lung cancer (p=0.0003).
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Future studies evaluating model performance for models including these risk factors may help
improve risk prediction for people meeting NCCN Group 2 criteria.
7.3 Sensitivity Analysis
Model discriminatory performance was largely unchanged when participants with missing family
history were removed from the sample. Similarly, model discriminatory performance was also
largely unchanged with recoding of uncertain family history of lung cancer from no lung cancer
to yes lung cancer.
There was also no significant impact on model discriminatory performance due to recoding of
personal history of cancer for both the scenario of patient self-report only and the scenario of
patient self-report only with exclusion of non-melanoma skin cancer, coded as having personal
history of cancer.
The results from these sensitivity analyses are not unexpected based on the lack of statistically
significant differences in the screening sample between percentage of participants with and
without lung cancer for family history of lung cancer and personal history of cancer (Table 8).
However, statistical significance (or lack of) for individual variables is not always predictive of
impact on model performance.26
In the screening program sample, model discriminatory performance was reduced when only
self-reported COPD was coded as having COPD. Mean model predicted risk of lung cancer
decreased for both cases and non-cases as did the difference in mean risk between them. The
difference in mean risk was no longer statistically significant between the cases and non-cases
at p</= 0.05. The percentage of participants in the screening program sample with COPD was
the sample characteristic with the largest difference between the screening program sample and
the model development and the NLST samples (73.4% vs. 9.1% and 5.1%, respectively).
Additionally, it was one of only 2 reported screening program sample characteristics that were
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significantly different between participants with lung cancer and participants without lung cancer.
Accurately assessing COPD status for lung cancer screening participants will be important for
discrimination in using the model for lung cancer screening participant selection.
7.4 Limitations
This study had several limitations. The model development sample had significantly different
risk predictor characteristics as compared to the screening program sample. In particular,
having COPD was more than 8 times as prevalent in the screening program sample as in the
model development sample. The differences in the predictor characteristics were likely due both
to differences in the actual sample characteristics as well as to data collection and coding
methodology differences between the studies.
The differences in the study designs, including follow-up duration (1.86 years vs. 6 years) have
resulted in reduced model performance in the screening program sample. Despite this, model
predictive capability was adequate to help individualize risk and to help inform the shared
decision making discussion.
The statistical analysis comparing the model calculated probabilities between groups used
simple means testing. There are multiple ways of comparing risks and risk differences between
groups that were not used for this study
The screening program sample was limited to 2 hospitals in the outskirts of a large metropolitan
city in the Northeastern United States. This sample may not be representative of all regions and
the results of the study not generalizable across all screening sites.
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Implications for Public Health
Lung cancer screening has only recently been recommended by the USPSTF and CMS and
thus there is not much experience with screening in clinical lung cancer screening programs.
Lung cancer risk prediction models have the potential to provide individualized risk predictions
for people helping to stratify the risk beyond the screening eligibility criteria. Screening the
highest risk individuals may help to optimize the risk benefit ratio for screening.
The CMS requirement for a shared decision making meeting with the use of one or more
decision aids for reimbursement prior to entering a lung cancer screening program provides a
window of opportunity to incorporate risk prediction models into the lung cancer screening
decision. This study demonstrated that the PLCOm2012noEd model has adequate to good
predictive capability, especially around the risk screening threshold, to use in individualizing the
risk discussion helping physicians and their patients better balance risk and patient values and
preferences. Studies such as this one are important in increasing physician confidence in risk
prediction models to encourage incorporation into clinical practice. Decision aid developers will
also benefit from including this model into interactive web based aids.
Studies such as this should be done at other screening sites with sufficient sample size, or once
sufficient sample size is attained. Additionally, a prospective, multi-center study, to assess
model predictive capability in clinical screening programs would provide both additional
evidence for use and increase adoption in clinical practice. Assessment of models with
alternate/additional risk predictor variables should be developed and assessed for the NCCN
Group 2 population. Ideal would be for CMS to cover NCCN Group 2, with evidence
development, to collect the data required to assess risk and develop accurate risk prediction
models.
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Other studies, such as the Fiscella et al. NHANES evaluation of predicted risk in different
race/ethnic groups,31 should be undertaken to identify the population at equivalent or higher risk
that is not covered by USPSF/CMS guidelines. Recent studies in people diagnosed with lung
cancer have shown half to two thirds do not meet the guidelines.33,34 As smoking rates continue
to decline, fewer people at risk will meet the guidelines. Having validated risk prediction models
will help refine the screening criteria with the potential for improved risk benefit ratios and more
lives saved.
Chapter 8: Conclusions
Lung cancer risk prediction model, PLCOm2012noEd, predictive performance in a clinical lung
cancer screening program was adequate to help patients and their physicians assess individual
risk of lung cancer relative to the recommended model risk screening threshold (1.51%) and to
supplement USPSTF and CMS screening program entry criteria for shared decision making.
An accurate assessment of COPD status is important for model predictive performance.
Model risk predictive capability for NCCN Group 2 did not match actual screening program lung
cancer results. This group was at equal risk to those meeting USPSTF/CMS criteria. More work
is needed to understand the additional risk factors needed to increase model performance for
this group.
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